Treatment with angiotensin II in COVID-19 patients may not be beneficial.
作者信息
Rysz Susanne, Jalde Francesca Campoccia, Oldner Anders, Eriksson Lars I, Lundberg Johan, Fagerlund Malin Jonsson
机构信息
Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Function Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.
出版信息
Crit Care. 2020 Sep 4;24(1):546. doi: 10.1186/s13054-020-03233-6.
Abstract
摘要
相似文献
1
Treatment with angiotensin II in COVID-19 patients may not be beneficial.在新冠肺炎患者中使用血管紧张素II进行治疗可能并无益处。
Crit Care. 2020 Sep 4;24(1):546. doi: 10.1186/s13054-020-03233-6.
2
Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?我们是否应该在新型冠状病毒肺炎相关的血管麻痹性休克中使用血管紧张素II输注？
Crit Care. 2020 Jul 9;24(1):407. doi: 10.1186/s13054-020-03144-6.
3
COVID-19 and the RAAS-a potential role for angiotensin II?新型冠状病毒肺炎与肾素-血管紧张素-醛固酮系统——血管紧张素II的潜在作用？
Crit Care. 2020 Apr 7;24(1):136. doi: 10.1186/s13054-020-02862-1.
4
Why the Use of Angiotensin II May be a Fatal Mistake in COVID-19.为何使用血管紧张素II可能是新冠疫情中的致命错误。
Shock. 2020 Nov;54(5):697-699. doi: 10.1097/SHK.0000000000001577.
5
Is Angiotensin II Unopposed a Good Thing?血管紧张素II不受拮抗是好事吗？
Anesth Analg. 2020 Sep;131(3):e170-e171. doi: 10.1213/ANE.0000000000005046.
6
Letter to the Editor - Circulating plasma levels of angiotensin II and aldosterone in patients with coronavirus disease 2019 (COVID-19): A preliminary report.致编辑的信——2019冠状病毒病（COVID-19）患者循环血浆中血管紧张素II和醛固酮水平：初步报告
Prog Cardiovasc Dis. 2020 Sep-Oct;63(5):702-703. doi: 10.1016/j.pcad.2020.07.006. Epub 2020 Jul 10.
7
Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers.2019冠状病毒病（COVID-19）感染与肾素-血管紧张素系统阻滞剂
JAMA Cardiol. 2020 Jul 1;5(7):745-747. doi: 10.1001/jamacardio.2020.1282.
8
Potential benefit of angiotensin II in COVID-19 patients: beyond reasonable doubt?血管紧张素II对COVID-19患者的潜在益处：毫无疑问？
Crit Care. 2020 Jun 9;24(1):324. doi: 10.1186/s13054-020-03027-w.
9
Angiotensin II, III, and IV may be important in the progression of COVID-19.血管紧张素II、III和IV可能在2019冠状病毒病的进展中起重要作用。
J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470320320972019. doi: 10.1177/1470320320972019.
10
In Response.作为回应。
Anesth Analg. 2020 Sep;131(3):e171. doi: 10.1213/ANE.0000000000005047.
引用本文的文献
1
Angiotensin I and II Stimulate Cell Invasion of SARS-CoV-2: Potential Mechanism via Inhibition of ACE2 Arm of RAS.血管紧张素I和II刺激新型冠状病毒的细胞侵袭：通过抑制肾素-血管紧张素系统的血管紧张素转换酶2分支的潜在机制。
Physiol Res. 2024 Mar 11;73(1):27-35. doi: 10.33549/physiolres.935198.
本文引用的文献
1
Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial.血管扩张性休克儿茶酚胺抵抗患者应用血管紧张素 II 治疗与肾素及生存关系的临床研究
Am J Respir Crit Care Med. 2020 Nov 1;202(9):1253-1261. doi: 10.1164/rccm.201911-2172OC.
2
Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series.血管紧张素 II 输注治疗新型冠状病毒肺炎相关血管舒张性休克：病例系列
Crit Care. 2020 May 15;24(1):227. doi: 10.1186/s13054-020-02928-0.
3
Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.血管紧张素转换酶 2：SARS-CoV-2 受体和肾素-血管紧张素系统的调节剂：庆祝 ACE2 发现 20 周年。
Circ Res. 2020 May 8;126(10):1456-1474. doi: 10.1161/CIRCRESAHA.120.317015. Epub 2020 Apr 8.
4
Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.从 2019 年新冠病毒感染患者中提取的临床和生化指标与病毒载量和肺部损伤有关。
Sci China Life Sci. 2020 Mar;63(3):364-374. doi: 10.1007/s11427-020-1643-8. Epub 2020 Feb 9.
5
Angiotensin II Brings More Questions Than Answers.血管紧张素 II 带来的问题比答案更多。
P T. 2018 Nov;43(11):685-687.
6
Angiotensin II for the Treatment of Vasodilatory Shock.血管扩张性休克的血管紧张素 II 治疗。
N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21.
7
The ATHOS-3 trial, angiotensin II and The Three Musketeers.ATHOS-3试验、血管紧张素II与《三个火枪手》
Crit Care Resusc. 2017 Mar;19(1):3-4.
Zotero 插件